A systematic review of economic evaluations of tyrosine kinase inhibitors of vascular endothelial growth factor receptors, mammalian target of rapamycin inhibitors and programmed death-1 inhibitors in metastatic renal cell cancer

References

• Rini B, Campbell S, Escudier B. Renal cell carcinoma. Lancet. 2009;373(9669):1119–1132.
   PubMed Web of Science ®Google Scholar
• Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up on behalf of the ESMO guidelines committee. Annals of Oncology. 2016;27(5):v58–v68. DOI:10.1093/annonc/mdw328
   PubMed Web of Science ®Google Scholar
• Clague J, Lin J, Cassidy A, et al. Family history and risk of renal cell carcinoma: results from a case-control study and systematic meta-analysis. Cancer Epidemiol Biomarkers Prev. 2009;18:801–807.
   PubMed Web of Science ®Google Scholar
• Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387:894–906.
   PubMed Web of Science ®Google Scholar
• Chow WH, Dong LM, Devesa SS. Chow epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7(5):245–257.
   PubMed Web of Science ®Google Scholar
• Coppin C, Kollmannsberger C, Le L, et al. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int. 2011;108(10):1556–1563.
   PubMed Web of Science ®Google Scholar
• Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21(16):3127–3132. Accessed 2014 Dec 9 Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2275327/
   PubMed Web of Science ®Google Scholar
• Van Harten WH, Wind A, De Paoli P, et al. Actual costs of cancer drugs in 15 European countries. Lancet Oncol. 2016;17:18–20.
   PubMed Web of Science ®Google Scholar
• Jonsson B, Hofmarcher T, Lindgren P, Wilking N. Comparator report on patient access to cancer medicines in Europe revisited (2016). IHE Report 2016:4, IHE:Lund Available at: http://ihe.se/en/publicering/cancer-medicines-in-europe-2 (accessed 2017 Aug 11
   Google Scholar
• Uyl-De Groot CA, Elisabeth GE, De Vries J, et al. Sullivan dispelling the myths around cancer care delivery: it’s not all about costs. Journal of Cancer Policy. 2014;2(2014):22–29.
   Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.
   PubMed Web of Science ®Google Scholar
• Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003;2:471–478.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124.
   PubMed Web of Science ®Google Scholar
• Cella D, Michaelson MD, Bushmakin AG, et al. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-a in a Phase III trial: final results and geographical analysis. Br. J. Cancer. 2010;102(4):658–664.
   PubMed Web of Science ®Google Scholar
• Aller EC, Maroto P, Kreif N, et al. Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain. Clin Transl Oncol. 2011;13:869–877. DOI:10.1007/s12094-011-0748-0
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584–3590.
   PubMed Web of Science ®Google Scholar
• Figlin RA, Hutson TE, Tomczak P et al. (2008) Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) [abstract 5024].Program and abstracts of the 44th American society of clinical oncology Annual Meeting May 30–June 3, Chicago, IL
   Google Scholar
• Négrier S, Figlin RA, Hutson TE et al. (2008) Overall survival with sunitinib versus interferon alfa as first-line treatment of metastatic renal cell carcinoma [abstract 588PD]. Program and abstracts of the 33rd European Society for Medical Oncology Congress, September 12 –16,Stockholm, Sweden
   Google Scholar
• Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:1280–1289.
   PubMed Web of Science ®Google Scholar
• Szczylik C, Demkow T, Staehler M et al. (2007) Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results [abstract# 5025]. Proceedings from the American Society of Clinical Oncology Conference, 2007,Chicago, IL. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S [June 20 Supplement]:5025
   Google Scholar
• Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet. 2007;370:2103–2111.
   PubMed Web of Science ®Google Scholar
• Escudier BJ, Bellmunt J, Négrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2009;28:2144–2150.
   Web of Science ®Google Scholar
• Wu B, Dong B, Xu Y, et al. Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource–limited setting. PLoS ONE. 2012;7(3):e32530. DOI:10.1371/journal.pone.0032530
   PubMed Web of Science ®Google Scholar
• Benedict Á, Figlin RA, Sandström P, et al. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. BJU International 2011;108:665–672
   Google Scholar
• Edit Rema´ K, Charbonneau C, Ne´Grier S, et al. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. Journal of Clinical Oncology. 2008 Aug 20;26:3995–4000
   Google Scholar
• Paz-Ares L, Del Muro JG, Grande E, et al. A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish national health system. Journal of Clinical Pharmacy and Therapeutics. 2010;35:429–438.
   PubMed Web of Science ®Google Scholar
• Purmonen T, Martikainen JA, Soini EO, et al. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland clinical. Therapeutics. 2008;30(2):382–392.
   Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma. Final results and analysis of prognostic factors. Cancer. 2010;116:4256–4265.
   PubMed Web of Science ®Google Scholar
• Mihajlović, J, Pechlivanoglou P, Sabo A, et al. Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia clinical. Therapeutics. 2013;35(12):1.
   Google Scholar
• Casciano R, Chulikavit M, Lorenzo GD, et al. Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib. Value in Health. 2011;14:846– 851.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–1813.
   PubMed Web of Science ®Google Scholar
• Wan XM, Peng LB, Ma JA, et al. Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives. Cancer. 2017 July 15;123:2634–2641.
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial. Lancet. 2011;378:1931–1939.
   PubMed Web of Science ®Google Scholar
• Petrou P. Cost-effectiveness analysis of axitinib through a probabilistic decision model. Expert Opinion on Pharmacotherapy. 2015;16:8,1233–1243.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, McCann L, et al. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N EnglJMed. 2014;370:1769–1770.
   PubMed Web of Science ®Google Scholar
• Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preferences for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol. 2014;32(14):1412–1418.
   PubMed Web of Science ®Google Scholar
• Capri S, Porta C, Delea TE. Cost-effectiveness of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma from an Italian national health service perspective clinical. Therapeutics. 2017;39(3):568-580.
   Google Scholar
• Amdahl Bs J, Diaz J, Park J, et al. Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada. Current Oncology. 2016 August;23(4):340.
   Web of Science ®Google Scholar
• Amdahl J, Diaz J, Sharma A, et al. Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom. PLoS ONE. 2017;12(6):e0175920.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061–1068. PMID: 20100962. DOI:10.1200/JCO.2009.23.9764
   PubMed Web of Science ®Google Scholar
• Delea TE, Amdahl J, Diaz J, et al. Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States. J Manag Care Spec Pharm. 2015 January;21(1):46-54.
   Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–2281.
   PubMed Web of Science ®Google Scholar
• Hoyle M, Green C, Thompson-Coon J, et al. Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma. Value in Health. 2010;13(1):61-68.
   Web of Science ®Google Scholar
• Hoyle M, Green C, Thompson-Coon J, et al. Cost-Effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma. Value in Health. 2010;Volume 13(Number 1):55–60.
   Web of Science ®Google Scholar
• Petrou P, Talias MA. Cost–effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus. Expert Review of Pharmacoeconomics & Outcomes Research. 2014;14(1):131–138.
   PubMed Web of Science ®Google Scholar
• Soerensen AV, Donskov F, Kjellberg J, et al. Geertsen PF Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2. Eur Urol. 2015 Sep;68(3):516–522. Epub 2014 Dec 18. DOI:10.1016/j.eururo.2014.12.017
   PubMed Web of Science ®Google Scholar
• Purmonen TT. Cost-effectiveness of sunitinib in metastatic renal cell carcinoma. Expert Review of Pharmacoeconomics & Outcomes Research. 2011;11(4):383–393.
   PubMed Web of Science ®Google Scholar